EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma

Sophia Millington-Ward iD, Arpad Palfi iD, Ciara Shortall, Laura K Finnegan iD, Ethan Bargroff, Iris J M Post iD, John Maguire, Mustapha Irnaten, Colm O Brien, Paul F Kenna, Naomi Chadderton iD, G Jane Farrar

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25168876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sophia Millington-Ward und 11 weiteren Autor:innen. Beteiligte Einrichtung: The School of Genetics and Microbiology, Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, D02VF25 Dublin, Ireland. Hauptthemen laut MEDLINE: Dependovirus, Glaucoma, Genetic Therapy, Retinal Ganglion Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland, Health Research Board, EU Marie Curie Innovation Training Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma, a leading cause of blindness, is a multifactorial condition that leads to progressive loss of retinal ganglion cells (RGCs) and vision. Therapeutic interventions based on reducing ocular hypertension are not always successful. Emerging features of glaucoma include mitochondrial dysfunction and oxidative stress. In the current study, NDI1-based gene therapy, which improves mitochondrial function and reduces reactive oxygen species, was delivered intraocularly via an adeno-associated viral vector (AAV). This AAV-NDI1 therapy protected RGCs from cell death in treated (1552.4 ± 994.0 RGCs/mm2) versus control eyes (1184.4 ± 978.4 RGCs/mm2, p < 0.05) in aged DBA/2J mice, a murine model of glaucoma. The photonegative responses (PhNRs) of RGCs were also improved in treated (6.4 ± 3.3 µV) versus control eyes (5.0 ± 3.1 µV, p < 0.05) in these mice. AAV-NDI1 also provided benefits in glaucomatous human lamina cribrosa (LC) cells by significantly increasing basal and maximal oxygen consumption rates and ATP production in these cells. Similarly, NDI1 therapy significantly protected H2O2-insulted primary porcine LC cells from oxidative stress. This study highlights the potential utility of NDI1 therapies and the benefits of improving mitochondrial function in the treatment of glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusGlaucomaGenetic TherapyRetinal Ganglion CellsDisease Models, AnimalOxidative StressGenetic VectorsAnimalsMiceHumansMitochondriaMice, Inbred DBAReactive Oxygen SpeciesSwine

Stichwörter der Autor:innen

AAVDBA/2J mouseNDI1ROSgene therapyglaucomalamina cribrosamitochondriaretina

Substanzen

Reactive Oxygen Species

Autor:innen und Institutionen

  • The School of Genetics and Microbiology, Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, D02VF25 Dublin, Ireland.
  • The Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin 2, D02XK51 Dublin, Ireland.
  • UCD Clinical Research Centre, Mater Misericordiae University Hospital, Dublin 7, D07K201 Dublin, Ireland.

ORCID-Profile: Sophia Millington-Ward, Arpad Palfi, Laura K Finnegan, Iris J M Post, Naomi Chadderton

Förderung

  • Science Foundation Ireland
  • Health Research Board
  • EU Marie Curie Innovation Training Network
  • Fighting Blindness Ireland - Health Research Charities Ireland
  • EU Marie Curie Innovative Training Network
  • Fighting Blindness Ireland—Health Research Charities Ireland

Zitieren

APA

Millington-Ward, S., Palfi, A., Shortall, C., Finnegan, L. K., Bargroff, E., Post, I. J. M., Maguire, J., Irnaten, M., O Brien, C., Kenna, P. F., Chadderton, N., & Farrar, G. J. (2024). AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168876

Vancouver

Millington-Ward S, Palfi A, Shortall C, Finnegan LK, Bargroff E, Post IJM, et al. AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168876

BibTeX
@article{MillingtonWard2024,
  author = {Millington-Ward, Sophia and Palfi, Arpad and Shortall, Ciara and Finnegan, Laura K and Bargroff, Ethan and Post, Iris J M and Maguire, John and Irnaten, Mustapha and O Brien, Colm and Kenna, Paul F and Chadderton, Naomi and Farrar, G Jane},
  title = {AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25168876}
}
Kostenlos starten →